Matthew Nelson
Leidos has landed a two-year, $22 million contract from the Defense Threat Reduction Agency to perform clinical studies that are meant to determine therapeutics for COVID-19 patients.
The company said Thursday it will employ a clinical trial prototype, which is designed to support collection of data in real-time, to simultaneously hold two clinical studies on drug combinations that could cure COVID-19.
The prototype is designed to gather, study and validate the degree of symptoms and potential clinical outcomes for patients through the use of electronic data capture technology.
DTRA aims to identify drug doses and regimens for coronavirus treatments that are safe and effective and to mitigate the neurocognitive effects of COVID-19.
The efforts will also focus on making the lung function of COVID-19 patients better in the long term.
The company has partnered with Syneos Health, Scope International and Personal Health Insights to carry out work under the project.
